BLSM: Lead EGFR inhibitor shows high efficacy and durability in resistant cancers, with key milestones ahead
BlossomHill presented strong clinical data for its lead EGFR inhibitor, showing high response rates and durability in resistant cancer populations, with a favorable safety profile and clear differentiation from competitors. Key milestones include a phase I meeting in late 2026 and multiple data rea…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.